Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 70

Cited In for PubMed (Select 18931004)

1.

Cholesterol, statins, and dementia: what the cardiologist should know.

Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS.

Clin Cardiol. 2015 Apr;38(4):243-50. doi: 10.1002/clc.22361. Epub 2015 Apr 13.

PMID:
25869997
3.

Statin use and cognitive function: population-based observational study with long-term follow-up.

Joosten H, Visser ST, van Eersel ME, Gansevoort RT, Bilo HJ, Slaets JP, Izaks GJ.

PLoS One. 2014 Dec 26;9(12):e115755. doi: 10.1371/journal.pone.0115755. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0118045.

4.

Vascular pathology of 20-month-old hypercholesterolemia mice in comparison to triple-transgenic and APPSwDI Alzheimer's disease mouse models.

Hohsfield LA, Daschil N, Orädd G, Strömberg I, Humpel C.

Mol Cell Neurosci. 2014 Nov;63:83-95.

PMID:
25447943
5.

Cholesterol balance in prion diseases and Alzheimer's disease.

Hannaoui S, Shim SY, Cheng YC, Corda E, Gilch S.

Viruses. 2014 Nov 20;6(11):4505-35. doi: 10.3390/v6114505.

6.

Molecular mechanisms underlying the effects of statins in the central nervous system.

McFarland AJ, Anoopkumar-Dukie S, Arora DS, Grant GD, McDermott CM, Perkins AV, Davey AK.

Int J Mol Sci. 2014 Nov 10;15(11):20607-37. doi: 10.3390/ijms151120607.

7.

The Cerebrovascular Basement Membrane: Role in the Clearance of β-amyloid and Cerebral Amyloid Angiopathy.

Morris AW, Carare RO, Schreiber S, Hawkes CA.

Front Aging Neurosci. 2014 Sep 19;6:251. doi: 10.3389/fnagi.2014.00251. eCollection 2014. Review.

8.

HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.

Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen RC; the Alzheimer's Disease Neuroimaging Initiative, Dufour R, Poirier J.

Mol Psychiatry. 2014 Jul 15. doi: 10.1038/mp.2014.81. [Epub ahead of print]

PMID:
25023145
9.

Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial.

Cooper SA, Caslake M, Evans J, Hassiotis A, Jahoda A, McConnachie A, Morrison J, Ring H, Starr J, Stiles C, Sullivan F.

Trials. 2014 Jun 3;15:202. doi: 10.1186/1745-6215-15-202.

10.
11.

Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline?

Kawamura T, Umemura T, Hotta N.

J Diabetes Investig. 2012 Oct 18;3(5):413-23. doi: 10.1111/j.2040-1124.2012.00234.x. Epub 2012 Aug 29. Review.

12.

Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors.

Shinohara M, Sato N, Shimamura M, Kurinami H, Hamasaki T, Chatterjee A, Rakugi H, Morishita R.

Front Aging Neurosci. 2014 Apr 23;6:71. doi: 10.3389/fnagi.2014.00071. eCollection 2014. Review.

13.

Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.

Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S.

BMC Med. 2014 Mar 22;12:51. doi: 10.1186/1741-7015-12-51. Review.

14.

The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease.

Grimm MO, Zimmer VC, Lehmann J, Grimm HS, Hartmann T.

Biomed Res Int. 2013;2013:814390. doi: 10.1155/2013/814390. Epub 2014 Feb 19. Review.

15.

Effects of statins on incident dementia in patients with type 2 DM: a population-based retrospective cohort study in Taiwan.

Chen JM, Chang CW, Chang TH, Hsu CC, Horng JT, Sheu WH.

PLoS One. 2014 Feb 10;9(2):e88434. doi: 10.1371/journal.pone.0088434. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e100019.

16.

CSF Apo-E levels associate with cognitive decline and MRI changes.

Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2014 May;127(5):621-32. doi: 10.1007/s00401-013-1236-0. Epub 2014 Jan 3.

17.
18.

Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Barone E, Di Domenico F, Butterfield DA.

Biochem Pharmacol. 2014 Apr 15;88(4):605-16. doi: 10.1016/j.bcp.2013.10.030. Epub 2013 Nov 11. Review.

19.
20.

Cross-talk of membrane lipids and Alzheimer-related proteins.

Walter J, van Echten-Deckert G.

Mol Neurodegener. 2013 Oct 22;8:34. doi: 10.1186/1750-1326-8-34. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk